These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 6910423)

  • 1. Protection of human plasma kallikrein from inactivation by C1 inhibitor and other protease inhibitors. The role of high molecular weight kininogen.
    Schapira M; Scott CF; Colman RW
    Biochemistry; 1981 May; 20(10):2738-43. PubMed ID: 6910423
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inactivation of kallikrein in human plasma.
    van der Graaf F; Koedam JA; Bouma BN
    J Clin Invest; 1983 Jan; 71(1):149-58. PubMed ID: 6184384
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Study of the effect of high molecular weight kininogen upon the fluid-phase inactivation of kallikrein by C1 inhibitor.
    Silverberg M; Longo J; Kaplan AP
    J Biol Chem; 1986 Nov; 261(32):14965-8. PubMed ID: 3639874
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High molecular weight kininogen potentiates the heparin-accelerated inhibition of plasma kallikrein by antithrombin: role for antithrombin in the regulation of kallikrein.
    Olson ST; Sheffer R; Francis AM
    Biochemistry; 1993 Nov; 32(45):12136-47. PubMed ID: 7692967
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interaction of human plasma kallikrein and its light chain with C1 inhibitor.
    van der Graaf F; Koedam JA; Griffin JH; Bouma BN
    Biochemistry; 1983 Sep; 22(20):4860-6. PubMed ID: 6556071
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inactivation of factor XIa by plasma protease inhibitors: predominant role of alpha 1-protease inhibitor and protective effect of high molecular weight kininogen.
    Scott CF; Schapira M; James HL; Cohen AB; Colman RW
    J Clin Invest; 1982 Apr; 69(4):844-52. PubMed ID: 7076850
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High molecular weight kininogen or its light chain protects human plasma kallikrein from inactivation by plasma protease inhibitors.
    Schapira M; Scott CF; James A; Silver LD; Kueppers F; James HL; Colman RW
    Biochemistry; 1982 Feb; 21(3):567-72. PubMed ID: 6175341
    [No Abstract]   [Full Text] [Related]  

  • 8. Interaction of human plasma kallikrein and its light chain with alpha 2-macroglobulin.
    van der Graaf F; Rietveld A; Keus FJ; Bouma BN
    Biochemistry; 1984 Apr; 23(8):1760-6. PubMed ID: 6202319
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Kinetic studies on surface-mediated activation of bovine factor XII and prekallikrein. Effects of kaolin and high-Mr kininogen on the activation reactions.
    Sugo T; Kato H; Iwanaga S; Takada K; Sakakibara S
    Eur J Biochem; 1985 Jan; 146(1):43-50. PubMed ID: 3871394
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hydrolysis of human high-molecular-mass kininogen by human plasma kallikrein. Proposal of a new model concept for the course of reaction in presence and absence of C1(-)-inhibitor.
    Wiedler J; Dutler H
    Biol Chem Hoppe Seyler; 1987 Sep; 368(9):1203-13. PubMed ID: 3675872
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Parallel mechanisms of high molecular weight kininogen action as a cofactor in kallikrein inactivation and prekallikrein activation reactions.
    Olson ST; Francis AM; Sheffer R; Choay J
    Biochemistry; 1993 Nov; 32(45):12148-59. PubMed ID: 8218292
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of high molecular weight kininogen in modulating the inactivation of human plasma kallikrein by plasma protease inhibitors.
    Schapira M; James A; Scott CF; Kueppers F; James HL; Cohen AB; Colman RW
    Adv Exp Med Biol; 1983; 156():131-41. PubMed ID: 6190364
    [No Abstract]   [Full Text] [Related]  

  • 13. Factor XII-independent activation of the bradykinin-forming cascade: Implications for the pathogenesis of hereditary angioedema types I and II.
    Joseph K; Tholanikunnel BG; Bygum A; Ghebrehiwet B; Kaplan AP
    J Allergy Clin Immunol; 2013 Aug; 132(2):470-5. PubMed ID: 23672780
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of plasma kallikrein by C1-inhibitor: role of endothelial cells and the amino-terminal domain of C1-inhibitor.
    Ravindran S; Grys TE; Welch RA; Schapira M; Patston PA
    Thromb Haemost; 2004 Dec; 92(6):1277-83. PubMed ID: 15583734
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Kinin release from high molecular weight kininogen by the action of Hageman factor in the absence of kallikrein.
    Wiggins RC
    J Biol Chem; 1983 Jul; 258(14):8963-70. PubMed ID: 6553057
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protein-protein interactions in contact activation of blood coagulation. Binding of high molecular weight kininogen and the 5-(iodoacetamido) fluorescein-labeled kininogen light chain to prekallikrein, kallikrein, and the separated kallikrein heavy and light chains.
    Bock PE; Shore JD; Tans G; Griffin JH
    J Biol Chem; 1985 Oct; 260(23):12434-43. PubMed ID: 3850090
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Contribution of plasma protease inhibitors to the inactivation of kallikrein in plasma.
    Schapira M; Scott CF; Colman RW
    J Clin Invest; 1982 Feb; 69(2):462-8. PubMed ID: 6173399
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunochemical studies of human high molecular weight kininogen and of its complexes with plasma prekallikrein or kallikrein.
    Kerbiriou DM; Bouma BN; Griffin JH
    J Biol Chem; 1980 May; 255(9):3952-8. PubMed ID: 6154706
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pathogenic mechanisms of bradykinin mediated diseases: dysregulation of an innate inflammatory pathway.
    Kaplan AP; Joseph K
    Adv Immunol; 2014; 121():41-89. PubMed ID: 24388213
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New and rapid functional assay for C1 inhibitor in human plasma.
    Schapira M; Silver LD; Scott CF; Colman RW
    Blood; 1982 Apr; 59(4):719-24. PubMed ID: 6174161
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.